ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.
Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?
The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.
Leqembi is an FDA-Approved Alzheimer’s treatment. Hospital infusions take an hour each. 2025 is looking to see a new 15-second autoinjector version. For some, it should even work at home.
Why are some of the new anti-Alzheimer’s antibodies better than others? With the FDA’s approval of Lecanemab and Donanemab, it’s worth staying on top of this topic’s latest research.
The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
VIDEO+ARTICLE: Multiple studies affirm bingo exercises attention, memory, and social connection all at once. Learn about its small but meaningful role in dementia care—when used the right way.
Posterior Cortical Atrophy, or PCA, is a specific form of Alzheimer’s that affects the back of the brain.
Author Terry Pratchett was diagnosed with it.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
It is one of the most beautiful Compensations of this life thatNo man can sincerely try to help anotherWithout helping himself.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
No spam, only news and updates.
